ResearcherChina Pharmaceutical UniversityNo recent work listed

Nan Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4102-2428; OpenAlex author ID A5100367555. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper

Papers 2

Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. Co-author DOI 10.1016/j.redox.2018.08.016 ↗
Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferative effects by DMAPT in pancreatic cance… Last author DOI 10.18632/oncotarget.16557 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yijun Chen · 2 shared papers, 2017–2018 · strength 0.21
- Paper Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. DOI 10.1016/j.redox.2018.08.016 ↗
- Paper Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferat… DOI 10.18632/oncotarget.16557 ↗
Jun Yang · 1 shared paper, 2018 · strength 0.12
- Paper Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. DOI 10.1016/j.redox.2018.08.016 ↗
Shi Chen · 1 shared paper, 2017 · strength 0.09
- Paper Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferat… DOI 10.18632/oncotarget.16557 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.